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COMMENTARY
Background: Memantine and cholinesterase inhibitors (ChEI) have distinct pharmacological
actions, and interest in the use of combination therapy for Alzheimer’s disease (AD) is
increasing.
Objective: To assess the available data on the use of memantine–ChEI combination and to
develop evidence-based recommendations.
Method: A systematic literature review with detailed discussion of the current evidence
base.
Results: Available data are limited: five studies of which two were randomized, double-blind,
placebo-controlled trials. One study indicated that memantine–ChEI combination is not
significantly more effective than placebo–ChEI in mild to moderate AD, but data were published
in abstract and poster form only. A second study indicated that the memantine–ChEI
combination is significantly more effective than placebo–ChEI in moderate to severe AD.
The calculated effect sizes of 0.36 on cognition and 0.12 on function, which were the primary
outcomes, were small, indicating a clinically minimal effect on cognition and no effect on
function. No data are available on whether combination treatment is more effective than
memantine monotherapy.
Conclusion: The available data do not justify the use of combination therapy. Future studies
should include three arms (memantine–placebo, placebo–ChEI, and memantine–ChEI), be of
an adequate size and duration, and use pragmatic measures. Clinicians should have full access
to data from any future trials.
Keywords: memantine, cholinesterase inhibitors, combination, Alzheimer’s disease,
randomised control studies, open-label studies
Introduction
Alzheimer’s disease (AD), the most common form of dementia, is a neurodegenerative
disorder that adversely affects memory, comprehension, judgment, thinking,
orientation, language, and calculation. Alzheimer’s disease places a considerable
progressive burden on the principal caregiver (Schneider et al 1999). The number of
people with AD in the USA is 4 million and is predicted to more than treble by 2050
(Sloane et al 2002). Kukull and Bowen (2002) estimated that AD comprises more
than 50% of total dementia cases. The economic impact of this illness is enormous,
exceeding US$100 billion annually in the USA (Boustani et al 2003).
In AD, degeneration of basal forebrain cholinergic pathways linked with the cortex
is thought to cause the cognitive deficiencies (Bartus et al 1982). Two pharmacological
treatments are available: memantine and the cholinesterase inhibitors (ChEI). These
affect different neurotransmitter systems. ChEIs block enzymes that metabolise
acetylcholine and therefore increase its levels (Becker 1991). Donepezil, galantamine,
and rivastigmine inhibit acetyl cholinesterase (Lane et al 2004). Inhibition of both
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butyrylcholinesterase and acetyl cholinesterase for
rivastigmine (Giacobini 2004), and nicotinic modulation for
galantamine (Samochocki et al 2000) may contribute to the
efficacy of these ChEIs.
The overactivation of glutamate, particularly N-methyl-
D-aspartate (NMDA)-selective receptors, has been
associated with the degeneration of cholinergic function seen
in AD (Francis 2003). Memantine may prevent glutamate-
induced neuronal damage by noncompetitive antagonism
of the NMDA receptor (Hartmann and Mobius 2003).
Current treatments may lack a clinically significant effect
and new treatment strategies are essential to assist in disease
management (AD2000 2004; NICE 2005). Combining
memantine’s potential neuroprotective effect with the
improvement in cholinergic functioning noted with a ChEI
may lead to additional therapeutic benefits (Wenk et al
2000). Recent animal studies have indicated a ceiling effect
on benefit in memory impairment and additive or synergistic
effects of combining memantine with a ChEI (Yamada et al
2005), which is the basic science rationale. We set out to
review the research evidence on combination.
Method
A computerized literature search of Medline (1966–July
2005), PsycINFO (1972–September 2005), Embase (1980–
July 2005), Cinhal (1982–September 2005) and the
Cochrane Collaboration was conducted. Keywords used
were: AD, randomized controlled trials (clinical trial, single-
blind method, double-blind method, random allocation),
open-label studies, cholinesterase inhibitors (donepezil,
rivastigmine, galantamine, galanthamine, and tacrine), and
memantine. The reference section of studies identified was
scrutinized, the relevant pharmaceutical manufacturers were
contacted for any unpublished studies, and the US trials
database (http://www.clinicalstudyresults.org/search/) was
examined. Single cases and non-AD studies were excluded.
Results
In total, five studies were identified. One trial is published
only in summary format online (FLI 2003) and in a poster
meta-analysis (Doody et al 2005). This poster, however,
contains only limited data (Doody et al 2005), and Forest
Laboratories were unable to provide more detailed
information (Forest Laboratories Inc 2005 July 7, pers
comm). One study was published in a peer-reviewed journal
(Tariot et al 2004). Three similar prospective studies have
been published only in abstract format (Pass et al 2004;
Patel et al 2004; Shua-Haim et al 2004).
Trial design
Two studies were multicenter, randomized, double-blind,
placebo-controlled (FLI 2003; Tariot et al 2004; Doody et
al 2005), and three studies were open label (Pass et al 2004;
Patel et al 2004; Shua-Haim et al 2004). The randomized,
controlled trials (RCTs) (FLI 2003; Tariot et al 2004; Doody
et al 2005) were not designed to determine the relative
efficacy compared with placebo of memantine monotherapy,
donepezil monotherapy, or combination therapy, but whether
memantine would provide additional benefit in a patient
already on a ChEI.
Study duration varied from 24 to 26 weeks. Tariot et al
(2004) randomized 203 patients to memantine and 201 to
placebo. The sample sizes of the open studies varied from
12 to 25 (Pass et al 2004; Patel et al 2004; Shua-Haim et al
2004). Patient numbers were not available for one study
(FLI 2003) except in a poster meta-analysis (n = 433) (Doody
et al 2005).
FLI (2003) maintained patients on a stable dose for a
ChEI (exact details not stated) for at least 6 months prior to
entry. Tariot et al (2004) maintained patients on donepezil
for at least 6 months, and at a stable dose of 5–10 mg daily
for at least 3 months prior to the study. None of the open
studies stated how long patients had been taking a ChEI
before memantine was begun (Pass et al 2004; Patel et al
2004; Shua-Haim et al 2004).
Diagnostic criteria were: National Institute of
Neurological and Communicative Disorders and Stroke–
Alzheimer Disease and Related Disorders Association
(NINCDS–ARDA) diagnosis of probable AD (FLI 2003;
Tariot et al 2004; Doody et al 2005); DSM-IV (APA 1994);
and NINCDS–ARDA for possible Alzheimer’s disease (Pass
et al 2004; Patel et al 2004; Shua-Haim et al 2004). Disease
stage ranged from mild to moderate AD in one RCT (FLI
2003; Doody et al 2005) to moderate to severe AD in the
other (Tariot et al 2004). The three open studies did not
specify the stage (Pass et al 2004; Patel et al 2004; Shua-
Haim et al 2004).
Assessment measures
Tariot et al (2004) assessed efficacy with the Severe
Impairment Battery (SIB) (Panisset et al 1994), a modified
19-item AD Cooperative Study–Activities of Daily Living
Inventory (ADCS–ADL19) (Galasko et al 1997), the
Clinician’s Interview-Based Impression of Change Plus
Caregiver Input (CIBIC-Plus) (Schneider et al 1997), the
Neuropsychiatric Inventory (NPI) (Cummings et al 1994),
and the Behavioral Rating Scale for Geriatric Patients (BGP)Neuropsychiatric Disease and Treatment 2006:2(2) 123
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(van der Kam et al 1971). FLI (2003) assessed global
outcomes (CIBIC-Plus) and Alzheimer’s Disease Assess-
ment Scale cognitive outcomes (ADAS-Cog); secondary
outcomes were the NPI and the ADCS–ADL23 (Doody et
al 2005). Three studies assessed memory objectively (exact
scale not stated) and used caregiver report to assess effect
on cognition and functioning (Pass et al 2004; Patel et al
2004; Shua-Haim et al 2004). None of the studies utilised
outcome instruments such as time to residential admission
or death.
Caregivers rated tolerability and adverse events in three
studies (Pass et al 2004; Patel et al 2004; Shua-Haim et al
2004). One study assessed emergent adverse events by
patient report and vital sign, physical examination,
laboratory, and electrocardiogram testing (Tariot et al 2004).
FLI (2003) reported adverse events in a pooled analysis of
six trials (Doody et al 2005).
Efficacy
Tariot et al (2004) reported that at week 24 using last
observation carried forward (LOCF) and observed cases
(OC), memantine with donepezil produced a statistically
significant improvement in the SIB, ADCS–ADL, CIBIC-
Plus, NPI, and BGP in patients with moderate to severe AD
compared with donepezil and placebo (see Table 1 for full
details).
It may be difficult to relate results from psychometric
scales to a clinical setting (Fox et al 2003; AD2000 2004)
and the clinical significance of combination therapy is
unclear. The effect size of 0.36 on cognition, although small
(Cohen 1988), is of comparable magnitude to that of the
ChEIs (Rockwood 2004). The effect size for function at
0.12 is very small and raises the issue of clinical relevance.
The relative improvements were limited when the full range
of each scale is considered, making it impossible to assess
response rates, and data were not made available despite
requests. Floor effects may have influenced the NPI and
BGP results, as the baseline readings indicated only mild
impairment.
A second trial failed to demonstrate that combination
therapy is significantly more effective than ChEI
monotherapy in patients with mild to moderate AD (FLI
2003; Doody et al 2005). Combination therapy did not
produce a statistically significant difference on global or
cognitive outcomes compared with placebo–ChEI. Over 24
weeks there was no change in cognition in the memantine–
ChEI group and the decline in cognition in the placebo–
ChEI group was less than expected. The small group
difference was not statistically significant (exact p value not
stated).
The three open studies noted improvements in carer-rated
cognition, but failed to demonstrate objective memory
improvements (Pass et al 2004; Patel et al 2004; Shua-Haim
et al 2004). Furthermore any effect noted in the open studies
should be treated cautiously because of the potential for
false positive outcomes owing to random variability, placebo
effects, and bias (Khan et al 2001).
Adverse events
Significantly more patients on memantine–donepezil
compared with placebo–donepezil completed one study
(85.1% [n = 172] vs 74.6% [n = 150], p = 0.01) (Tariot et al
2004), suggesting that the combination was not associated
with significantly greater side effect burden than the ChEI
alone. Adverse events that occurred twice as frequently with
memantine were: confusion (7.9% vs 2.0%; p = 0.01), and
headache (6.4% vs 2.5%; p = 0.09) (Tariot et al 2004).
Adverse events occurred in 78% of patients on memantine,
and 72% of patients on placebo (p not stated) (Tariot et al
2004). This high rate of adverse events may provide an
accurate reflection of adverse events in the wider population
of nonstudy patients. Future trials should take into account
the fact that the patient selection criteria of placebo-
controlled studies may overestimate the incidence of adverse
events associated with placebo (Bandolier 2003) owing to
the nature of the underlying disorder.
Table 1 Efficacy outcomes (least squares mean score [SE])
baseline to week 24 change – memantine–donepezil vs
placebo–donepezil (Tariot et al 2004)
Rating
scale LOCF Observed cases
SIB 0.9 (0.67) vs –2.5 (0.69); 1.0 (0.70) vs –2.4 (0.74);
p < 0.001 p < 0.001
ADCS–ADL –2.0 (0.50) vs –3.4 (0.51); –1.7 (0.51) vs –3.3 (0.55);
p = 0.03 p = 0.02
CIBIC–Plus 4.41 (0.074) vs 4.66 (0.075); 4.38 (0.081) vs 4.64 (0.087);
 p = 0.03 p = 0.03
NPI –0.1 (0.98) vs 3.7 (0.99); –0.5 (0.99) vs 2.9 (1.06);
p = 0.002 p = 0.01
BGP 0.8 (0.37) vs 2.3 (0.38); 0.6 (0.37) vs 2.2 (0.40);
dependency p = 0.001 p = 0.001
care subscale
Abbreviations: ADCS–ADL, Alzheimer’s disease Cooperative Study–Activities
of Daily Living Inventory (Galasko et al 1997); BGP, Behavioral Rating Scale for
Geriatric Patients (van der Kam et al 1971); CIBIC-Plus, Clinician’s Interview-
Based Impression of Change Plus Caregiver Input (Schneider et al 1997); LOCF,
last observation carried forward; NPI, Neuropsychiatric Inventory (Cummings et
al 1994); SIB, Severe Impairment Battery (Panisset et al 1994).Neuropsychiatric Disease and Treatment 2006:2(2) 124
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One study has not mentioned tolerability to date except
as a pooled figure, which makes specific commentary
impossible (FLI 2003; Doody et al 2005). Discontinuation
rates of 7.9% with placebo and 6% with memantine may
indicate that memantine lacks efficacy in the milder stages
of AD (Doody et al 2005). No patients discontinued
treatment or reported adverse events in the open studies (Pass
et al 2004; Patel et al 2004; Shua-Haim et al 2004).
Conclusion
On the current available evidence, the use of memantine–
ChEI combination therapy cannot be recommended as there
is no evidence that combination therapy is more effective
than memantine monotherapy (Tariot et al 2004). On
common outcome measures, Reisberg et al (2003)
demonstrated a larger memantine monotherapy–placebo
signal than the memantine–donepezil combination/placebo–
donepezil signal (Tariot et al 2004). The negative mild AD
study (FPI 2003; Doody et al 2005) in our opinion backs
the US Food and Drug Administration decision not to allow
license extension to mild AD (FDA 2005).
The difficulty in obtaining full access to relevant studies
is of concern and makes developing evidence-based
recommendations problematic. Clinicians should have full
access studies as directed by new US legislation (http://
www.clinicalstudyresults.org/search/). The publication of
a meta-analysis that includes dementia at various stages in
advance of full publication or full data disclosure may
obscure negative results (Lexchin et al 2003; Doody et al
2005).
Healthcare provider guidelines need to consider the
economic impact of combination prescribing in a situation
where the cost benefits of cognitive is already controversial
(NICE 2005; Maidment et al 2006).
No adequate study has yet been presented to determine
whether ChEI combined with memantine has a synergistic
effect. Further studies including three arms: memantine–
placebo, placebo–ChEI, and memantine–ChEI, are required
to develop the evidence base. Studies should concentrate
on patients with moderate to severe AD and include a 12-
month extension arm to determine if efficacy is sustained.
Active treatments should be assessed for a clinical effect in
addition to a statistically significant effect. Future studies
should evaluate the efficacy of combination therapy in
non-AD dementia and include formal economic evaluations
and pragmatic efficacy assessments such as time to
residential facility.
Key points
On the current dataset the use of memantine–ChEI
combination therapy cannot be endorsed.
Future studies should include three arms: memantine–
placebo, placebo–ChEI, and memantine–ChEI.
Before adding in memantine, ChEIs should be
discontinued or, once on therapeutic dose of memantine, be
discontinued in a tapered manner with regular review.
Clinicians should be granted full access to the data at
the earliest opportunity.
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